Loncastuximab-Rituximab Boosts Response Rates in R/R Follicular Lymphoma

(MedPage Today) -- SAN DIEGO -- The combination of loncastuximab tesirine (Zynlonta) and rituximab achieved promising response rates in patients with relapsed or refractory follicular lymphoma (R/R FL), according to a phase II trial.
The single...